RBCC Nears Finalization of Partnership Agreement with Leading-Edge Pharmacogenomics Labs
March 06 2013 - 5:00AM
Business Wire
Rainbow Coral Corp. (OTCBB: RBCC), a biotech company focused on
delivering new medical technologies and innovations, today reports
its anticipation of partnering with a cutting-edge genome-mapping
facility in Houston in the next few weeks.
The genetic testing sector is one of the fastest-growing
segments of the global biotech industry, with some market experts
expecting it to reach $2.2 billion by 2017. The cutting-edge
science of pharmacogenomics is a field of study resulting from the
Human Genome Project that seeks to help doctors assess genetic
variations in patients in order to create more effective, optimized
drug treatment plans.
RBCC sees it as the future of medicine.
“This is the next evolution in personalized medicine,” said RBCC
CEO Patrick Brown. “Important differences in drug metabolism and
response from person to person are often rooted in our genes. By
studying a patient’s genotype, doctors can eliminate the
trial-and-error approach to tailoring a safer, more efficient and
more effective drug treatment plan.”
RBCC is turning its full attention to the exploration of new
promising opportunities now that the company will no longer be
partnering with Amarantus Biosciences, which has elected to pursue
other opportunites. RBCC wishes Amarantus much success moving
forward, and remains open to future partnering opportunities with
the company.
In addition to its pharmacogenomics talks, RBCC is also
currently working on a joint venture agreement with a privately
held drug delivery company that could soon make local delivery of
biologic agents and small molecules safer, more effective and more
convenient than ever before.
For more information on Rainbow BioSciences’ current projects,
please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research
technology innovations to compete alongside companies such as
Bristol Myers Squibb Co. (NYSE: BMY), Biogen Idec Inc.
(NASDAQ: BIIB), Abbott Laboratories (NYSE: ABT) and Amgen
Inc. (NASDAQ: AMGN).
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of
Rainbow Coral Corp. (OTCBB: RBCC). The Company continually
seeks out new partnerships with biotechnology developers to deliver
profitable new medical technologies and innovations. For more
information on our growth-oriented business initiatives, please
visit www.RainbowBioSciences.com. For investment information and
performance data on the Company, please
visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995: This news release contains forward-looking
information within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, including statements that include the words
"believes," "expects," "anticipate" or similar expressions. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause the actual results,
performance or achievements of the Company to differ materially
from those expressed or implied by such forward-looking statements.
In addition, description of anyone's past success, either financial
or strategic, is no guarantee of future success. This news release
speaks as of the date first set forth above and the Company assumes
no responsibility to update the information included herein for
events occurring after the date hereof.